))
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
Manage episode 414417314 series 3381434
Treść dostarczona przez ReachMD. Cała zawartość podcastów, w tym odcinki, grafika i opisy podcastów, jest przesyłana i udostępniana bezpośrednio przez ReachMD lub jego partnera na platformie podcastów. Jeśli uważasz, że ktoś wykorzystuje Twoje dzieło chronione prawem autorskim bez Twojej zgody, możesz postępować zgodnie z procedurą opisaną tutaj https://pl.player.fm/legal.
CME credits: 0.50
Valid until: 15-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/gprc5d-targeted-bispecifics-in-relapsedrefractory-multiple-myeloma-practical-expert-consensus-on-a-new-target-with-unique-adverse-events/24141/
GPRC5D-directed therapy is associated with impressive overall response rates and substantially positive clinical outcomes in heavily pretreated relapsed/refractory multiple myeloma. Identification and appropriate management of treatment-emergent adverse events is important to ensure that patients can stay on therapy safely to achieve optimal outcomes. In this educational podcast, myeloma experts weigh in on best-practice management strategies for these toxicities. =
…
continue reading
Valid until: 15-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/gprc5d-targeted-bispecifics-in-relapsedrefractory-multiple-myeloma-practical-expert-consensus-on-a-new-target-with-unique-adverse-events/24141/
GPRC5D-directed therapy is associated with impressive overall response rates and substantially positive clinical outcomes in heavily pretreated relapsed/refractory multiple myeloma. Identification and appropriate management of treatment-emergent adverse events is important to ensure that patients can stay on therapy safely to achieve optimal outcomes. In this educational podcast, myeloma experts weigh in on best-practice management strategies for these toxicities. =
674 odcinków
Udostępnij
